STOCK TITAN

Journey Medical (DERM) 2026 meeting backs all directors and re-approves KPMG

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Journey Medical Corporation reported the results of its 2026 annual stockholder meeting held via virtual platform. Stockholders representing 16,145,526 shares of common stock and 6,000,000 shares of Class A common stock, together 81% of the 27,346,466 shares entitled to vote, were present, establishing a quorum.

All six director nominees were elected, each receiving over 31.7 million votes in favor, with broker non-votes of 6,515,971 for each nominee. Stockholders also ratified KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 39,374,407 votes for, 50,168 against, and 202,042 abstentions.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Quorum voting power 81% Shares represented at 2026 annual meeting
Shares entitled to vote 27,346,466 shares Total shares entitled to vote at 2026 meeting
Common shares outstanding 21,346,466 shares Common stock outstanding as of April 28, 2026 record date
Class A shares outstanding 6,000,000 shares Class A common stock outstanding as of April 28, 2026
Class A votes per share 3.91 votes/share Voting entitlement for each Class A share
Votes for highest-supported director 32,972,865 votes Votes for Michael Pearce election
Votes for auditor ratification 39,374,407 votes Votes in favor of KPMG LLP for 2026
Votes against auditor ratification 50,168 votes Votes against KPMG LLP for 2026
quorum financial
"or together 81% of the 27,346,466 shares entitled to vote, were represented in person or by proxy, constituting a quorum."
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
broker non-votes financial
"Director | | Votes For | | Votes Withheld | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
record date financial
"As of the April 28, 2026 record date for the determination of the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
proxy statement on Schedule 14A regulatory
"The two proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting"
A proxy statement on Schedule 14A is the official, regulator-filed packet of information companies send to shareholders before a vote, like a mailed agenda and background materials for a town-hall meeting. It explains who is running for the board, items up for approval, key executive pay and risks, and how to vote — details investors use to judge leadership, governance and potential changes that can affect share value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001867066 0001867066 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 24, 2026

 

Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)

 

Delaware  001-41063  47-1879539
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)  (IRS Employer Identification No.)

 

9237 E Via de Ventura Blvd., Suite 105

Scottsdale, AZ 85258

(Address of Principal Executive Offices)

 

(480) 434-6670

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act.
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  
¨Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock DERM Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

  

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 24, 2026, Journey Medical Corporation (the “Company”) held its 2026 Annual Meeting at 11:00 a.m. Eastern Time by means of an online virtual meeting platform. Stockholders representing 16,145,526 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company and 6,000,000 shares of the Company’s Class A Common Stock of the Company, par value $0.0001 per share, or together 81% of the 27,346,466 shares entitled to vote, were represented in person or by proxy, constituting a quorum.

 

At the 2026 Annual Meeting, the following two proposals were approved: (i) the election of six directors to hold office until the 2027 annual meeting of stockholders or until their successors are duly elected and qualified; and (ii) the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The two proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the SEC on April 30, 2026.

 

As of the April 28, 2026 record date for the determination of the stockholders entitled to notice of, and to vote at, the 2026 Annual Meeting, 21,346,466 shares of the Company’s Common Stock were outstanding and eligible to vote with an aggregate of 21,346,466 votes, and 6,000,000 shares of the Company’s Class A Common Stock, each such share of Class A Common Stock entitled to 3.91 votes per share, were outstanding and eligible to vote with an aggregate of 23,481,091 votes, as determined in accordance with Article IV, Section 3.2 of the Company’s Third Amended and Restated Certificate of Incorporation.

 

Proposal 1

 

The votes with respect to the election of six directors to hold office until the 2027 annual meeting of stockholders were as follows:

 

Director   Votes For   Votes
Withheld
  Broker Non-Votes
Lindsay A. Rosenwald, M.D.   32,559,583   551,063   6,515,971
Claude Maraoui   32,972,638   138,008   6,515,971
Neil Herskowitz   31,728,709   1,381,937   6,515,971
Justin Smith   32,873,028   237,618   6,515,971
Miranda Toledano   32,513,215   597,431   6,515,971
Michael Pearce   32,972,865   137,781   6,515,971

 

Proposal 2

 

The vote with respect to the ratification of KPMG LLP as the Company’s independent registered accounting firm for the year ending December 31, 2026 was as follows:

 

Total Votes For   Total Votes Against   Abstentions
39,374,407   50,168   202,042

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Journey Medical Corporation
   
  (Registrant)
   
Date: June 25, 2026  
  By: /s/ Claude Maraoui
    Claude Maraoui
    Chief Executive Officer, President and Director

 

 

FAQ

What did Journey Medical (DERM) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing six directors and ratifying KPMG LLP as independent auditor for 2026. Both proposals passed, confirming the board slate and continuing KPMG’s role as the company’s registered public accounting firm.

What percentage of Journey Medical (DERM) voting power was present at the 2026 meeting?

Shares representing 81% of the 27,346,466 shares entitled to vote were present. This included 16,145,526 common shares and 6,000,000 Class A shares, satisfying quorum requirements for conducting the meeting’s business.

How many votes supported Journey Medical (DERM) director elections in 2026?

Each of the six director nominees received over 31.7 million votes for election. Votes for individual nominees ranged from 31,728,709 to 32,972,865, with consistent broker non-votes of 6,515,971 for each director.

Was KPMG LLP ratified as Journey Medical (DERM) auditor for 2026?

Yes. Stockholders ratified KPMG LLP as independent registered public accounting firm for 2026 with 39,374,407 votes for, 50,168 against, and 202,042 abstentions, indicating strong support for continuing the existing audit relationship.

How are Journey Medical (DERM) Class A shares counted for voting?

For the April 28, 2026 record date, 6,000,000 Class A common shares were outstanding, each entitled to 3.91 votes, totaling 23,481,091 votes. This voting structure is defined in the company’s Third Amended and Restated Certificate of Incorporation.

What were Journey Medical (DERM) total votes eligible at the 2026 record date?

At the April 28, 2026 record date, 21,346,466 common shares carried 21,346,466 votes, and 6,000,000 Class A shares carried 23,481,091 votes, for combined eligible voting power reflecting both classes’ structures.

Filing Exhibits & Attachments

3 documents